Karen Cavanaugh
Mayo Clinic
Cardiac function curveInternal medicineSurgeryMagnetic resonance imagingCardiologyAdverse effectCoronary circulationBleedUmbilical cordCardiac catheterizationHeart failureVentricleStem-cell therapyHypoplastic left heart syndromeImplantable loop recorderTricuspid valveContext (language use)Heart diseaseSurgical repairCell basedPhases of clinical researchPhysical examinationMedicineEjection fraction
3Publications
2H-index
27Citations
Publications 3
Newest
#2Joseph A. Dearani (UR: University of Rochester)H-Index: 95
#5Bryan C. Cannon (UR: University of Rochester)H-Index: 29
Last. Karen Cavanaugh (Mayo Clinic)H-Index: 2
view all 13 authors...
Abstract Background The objective of this study is to assess the safety and early impact of intramyocardial delivery of autologous bone marrow-derived mononuclear cells (BM-MNC) at time of surgical Ebstein repair. Methods Patients with EA (ages 6 months to 30 years) scheduled to undergo repair of the TV were eligible to participate in this open label, non-randomized Phase I clinical trial. BM-MNC target dose was 1-3 million cells/kg. Ten patients have undergone surgical intervention and cell del...
2 CitationsSource
#1Harold M. Burkhart (OU: University of Oklahoma)H-Index: 53
#2Muhammad Yasir Qureshi (Mayo Clinic)H-Index: 10
Last. Joan WobigH-Index: 1
view all 35 authors...
Abstract Objectives Staged surgical palliation for hypoplastic left heart syndrome results in an increased workload on the right ventricle serving as the systemic ventricle. Concerns for cardiac dysfunction and long-term heart failure have generated interest in first-in-infant, cell-based therapies as an additional surgical treatment modality. Methods A phase 1 clinical trial was conducted to evaluate the safety and feasibility of direct intramyocardial injection of autologous umbilical cord blo...
21 CitationsSource
#1Muhammad Yasir Qureshi (Mayo Clinic)H-Index: 10
#2Allison K. Cabalka (Mayo Clinic)H-Index: 30
Last. Karen MillerH-Index: 2
view all 19 authors...
Abstract Myocardial dysfunction after Fontan palliation for univentricular congenital heart disease is a challenging clinical problem. The medical treatment has a limited impact, with cardiac transplant being the ultimate management step. Cell-based therapies are evolving as a new treatment for heart failure. Phase 1 clinical trials using regenerative therapeutic strategies in congenital heart disease are ongoing. We report the first case of autologous bone marrow–derived mononuclear cell admini...
6 CitationsSource